Associated Papers
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
41152984 (PubMed )
Supplement: 13073_2025_1564_MOESM2_ESM.xlsx › Table_S5
BTK autoinhibition analyzed by high-throughput swaps of SH2 domains.
Eisen TJ et al.
Proceedings of the National Academy of Sciences of the United States of America, 2025
Clinical and molecular analysis of 49 patients with X-linked agammaglobulinemia from a single center in Argentina.
Basile N et al.
Journal of Clinical Immunology, 2009
Genome wide analysis of pathogenic SH2 domain mutations.
Lappalainen I et al.
Proteins, 2008
Bruton tyrosine kinase gene mutations in Argentina.
Danielian S et al.
Human Mutation, 2003
Bruton's tyrosine kinase is essential for hydrogen peroxide-induced calcium signaling.
Qin S et al.
Biochemistry, 2001
Six X-linked agammaglobulinemia-causing missense mutations in the Src homology 2 domain of Bruton's tyrosine kinase: phosphotyrosine-binding and circular dichroism analysis.
Mattsson PT et al.
Journal of Immunology (baltimore, Md. : 1950), 2000
Involvement of Bruton's tyrosine kinase in FcepsilonRI-dependent mast cell degranulation and cytokine production.
Hata D et al.
The Journal of Experimental Medicine, 1998
Phosphatidylinositol-3,4,5-trisphosphate (PtdIns-3,4,5-P3)/Tec kinase-dependent calcium signaling pathway: a target for SHIP-mediated inhibitory signals.
Scharenberg AM et al.
The Embo Journal, 1998
Btk/Tec kinases regulate sustained increases in intracellular Ca2+ following B-cell receptor activation.
Fluckiger AC et al.
The Embo Journal, 1998
Constitutive membrane association potentiates activation of Bruton tyrosine kinase.
Li T et al.
Oncogene, 1997
Activation of Bruton's tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain.
Li T et al.
Immunity, 1995
Select a paper to view details